Form 8-K Harmony Biosciences Hold For: Apr 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Harmony Biosciences (HRMY) Enters into a License Agreement with Bioprojet
April 11, 2024 8:37 AM EDTOn April 11, 2024, Harmony Biosciences (NASDAQ: HRMY). announced that its subsidiary Harmony Biosciences, LLC (Harmony) entered into a sublicense agreement with Bioprojet Société Civile de Recherche and Bioprojet Pharma SAS (Bioprojet) for an orexin-2 receptor agonist (OX2R) (the Licensed Compound) to be evaluated for the treatment of narcolepsy and potential other indications (the Sublicense). Under the Sublicense, Harmony... More
